Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL trial of bacterial vaginosis pre-treatment options followed by LC115
PACTR202605684486333Phase 1Not yet recruiting
- Sponsor
- CAPRISA
- Start
- Jun 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LC115, dequalinium and metronidazole in bacterial vaginosis (BV) (3 arms), sponsored by CAPRISA. Primary endpoints: Safety of LC115 and BV pre-treatments and Lactobacillus crispatus vaginal dominance at V6. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
LC115dequaliniummetronidazole
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on PACTR202605684486333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605684486333.